Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The broker is feeling very bullish about the sleep disorder treatment company. The post Goldman Sachs tips ResMed shares to ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

Nunez, MD, and Chief Medical Officer with ResMed. Most CPAP machines include a mask that covers your nose and mouth and helps you breathe by increasing air pressure in the throat to prevent your ...

About half of the people with prescribed CPAP machines don't use them as prescribed or stop using them altogether because the mask is uncomfortable ... also bundles for ResMed AirSense 10 ($ ...

ResMed is best known for creating medical devices for treating diseases such as sleep apnea and COPD. This includes making masks that are used with devices like CPAP machines, designed to be ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...